Savvas Sarantos

Dr. Savvas Sarantos

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Stamatios LampsasStamatios Lampsas
Stamatios Lampsas
MXMaria Xenou
Maria Xenou
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
ALAntonios Lysandrou
Antonios Lysandrou
GSGerasimos Siasos
Gerasimos Siasos
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely determined by variations in the Lp(a) gene (LPA) locus encoding apo(a). Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL), and its role adversely affects vascular inflammation, atherosclerotic lesions, endothelial function and thrombogenicity, which pathophysiologically leads to cardiovascular (CV) events. Despite this crucial role of Lp(a), its measurement lacks a globally unified method, and, between different laboratories, results need standardization. Standard antilipidemic therapies, such as statins, fibrates and ezetimibe, have a mediocre effect on Lp(a) levels, although it is not yet clear whether such treatments can affect CV events and prognosis. This narrative review aims to summarize knowledge regarding the mechanisms mediating the effect of Lp(a) on inflammation, atherosclerosis and thrombosis and discuss current diagnostic and therapeutic potentials.

Verified
Journal Article
Open access
PDF file
AGATHINA GOLIOPOULOU
ATHINA GOLIOPOULOU
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
PTPanagiotis Theofilis
Panagiotis Theofilis
VTVasiliki Tsigkou
Vasiliki Tsigkou
GMGeorge Makavos
George Makavos
GSGerasimos Siasos
Gerasimos Siasos
Background: The association of obesity with right ventricular function and the interplay between right heart and pulmonary circulation is incompletely understood. We evaluate the role of obesity as a determinant of right ventricular-pulmonary artery coupling (RVAC). Methods: We retrospectively studied consecutive subjects without overt cardiovascular or pulmonary disease. Subjects were stratified according to body mass index (BMI) as normal weight, overweight, or obese. A transthoracic echocardiographic study was used to assess left and right heart functional and structural parameters. RVAC was assessed using the ratio of peak systolic velocity of the tricuspid annulus to pulmonary artery systolic pressure (PASP). Results: A total of 145 subjects were enrolled with diabetes mellitus incidence higher in obese. There was no difference in left ventricular global longitudinal strain and in PASP or markers of right ventricular systolic function based on BMI. RVAC was significantly lower in the presence of obesity (normal weight: 0.52 (0.19) cm·(sec·mmHg)−1 vs. overweight: 0.47 (0.16) cm·(sec·mmHg)−1 vs. obese: 0.43 (0.14) cm·(sec·mmHg)−1, p = 0.03), even after adjustment for confounders (β: −0.085, 95% confidence interval: −0.163, −0.009, p = 0.029). Conclusions: Our findings highlight the relationship between metabolic impairment and RVAC, suggesting additional mechanisms for heart failure development observed in obese subjects.

1 November 2022 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
Stamatios LampsasStamatios Lampsas
Stamatios Lampsas
NSNektarios Souvaliotis
Nektarios Souvaliotis
SSSavvas Sarantos
Savvas Sarantos
GSGerasimos Siasos
Gerasimos Siasos
MVManolis Vavuranakis
Manolis Vavuranakis
Background: Coronavirus Disease-19 (COVID-19) is implicated in endotheliitis which adversely affects cardiovascular events. The impact of vaccination with COVID-19 on the clinical outcome of patients is documented. Objective: To evaluate the impact of vaccination with COVID-19 on severe acute respiratory syndrome, coronavirus-2 (SARS-CoV-2) infection-related endothelial impairment. Methods: We enrolled 45 patients hospitalized for COVID-19 (either vaccinated or not against SARS-CoV-2). Clinical and laboratory data were collected, and brachial artery flow-mediated dilation (FMD) was evaluated. Subjects without COVID-19 were used as the control group. Results: There was no difference in age (64.7±7.5 years vs. 61.2±11.1 years vs. 62.4±9.5, p=0.28) and male sex (49% vs. 60% vs. 52%, p=0.71), between control subjects, vaccinated, and unvaccinated subjects with COVID-19 respectively. Of the patients with COVID-19, 44% were vaccinated against SARS-CoV-2. Unvaccinated COVID-19 patients had significantly impaired FMD compared to vaccinated COVID-19 patients and to Control subjects (2.05±2.41 % vs. 7.24±2.52 % vs. 7.36±2.94 %, p<0.001). Importantly, post hoc tests revealed that unvaccinated COVID-19 patients had significantly impaired FMD from both Vaccinated COVID-19 subjects (p<0.001) and form Control subjects (p<0.001). There was no difference in FMD between the control group and the vaccinated COVID-19 group (p=0.99). Conclusion: Hospitalized patients with COVID-19 present endothelial dysfunction in the acute phase of the disease. Endothelial function in unvaccinated patients with COVID-19 is impaired compared to control subjects as well compared to vaccinated patients with COVID-19. Vaccinated hospitalized subjects with COVID-19 do not show endothelial dysfunction, strengthening the protective role of vaccination against SARS-CoV-2.

24 September 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
George E. ZakynthinosGeorge E. Zakynthinos
George E. Zakynthinos
NTNiki Tripyla
Niki Tripyla
NKNikolaos Kokkinos
Nikolaos Kokkinos
OKOurania Katsarou
Ourania Katsarou
IGIoannis Gialamas
Ioannis Gialamas
GSGerasimos Siasos
Gerasimos Siasos
Shock is traditionally classified according to its primary etiology—septic, hypovolemic, obstructive, or cardiogenic—yet these syndromes frequently converge on a common feature: disturbances of cardiac performance, ventricular loading, and tissue perfusion. Despite distinct initiating mechanisms, altered preload and afterload, ventricular interdependence, vascular dysfunction, maladaptive neurohormonal responses, and, in selected states, impaired myocardial contractility may ultimately reduce effective forward flow and tissue perfusion. Echocardiography provides a rapid, noninvasive bedside tool for characterizing these evolving cardiovascular effects. It enables assessment of left and right ventricular function, cardiac filling, preload responsiveness, pulmonary and systemic venous congestion, fluid tolerance, and broader hemodynamic profiles while facilitating recognition of reversible causes such as cardiac tamponade, acute pulmonary embolism, or severe hypovolemia. This allows clinicians to move beyond static etiologic classifications toward a physiology-based assessment of shock. Beyond diagnosis, echocardiography can inform fluid resuscitation and vasoactive or inotropic therapy. Serial assessment also permits evaluation of therapeutic response and evolving hemodynamic phenotypes. This review synthesizes the mechanisms of cardiac involvement across shock syndromes and highlights echocardiography as a unifying tool for their evaluation and management. By integrating pathophysiology, bedside imaging, and hemodynamic treatment, we propose a physiology-based framework that complements traditional shock classification and may improve diagnostic precision and individualized management in critically ill patients.

17 November 2026 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
ARAnastasios Roumeliotis
Anastasios Roumeliotis
NVNikolaos Vythoulkas-Biotis
Nikolaos Vythoulkas-Biotis
AGAlexios Giannakodimos
Alexios Giannakodimos
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
OKOurania Katsarou
Ourania Katsarou
GSGerasimos Siasos
Gerasimos Siasos
Background: Bariatric surgery and pharmacological weight-loss therapies improve cardiometabolic risk factors. However, direct head-to-head comparisons assessing their impact on cardiovascular outcomes remain limited. We performed an exploratory meta-analysis to compare bariatric surgery and pharmacological weight-loss therapies on major clinical outcomes in adults with obesity. Methods: A systematic literature search using PubMed and Scopus databases was conducted. Randomized and observational studies comparing bariatric surgery or incretin receptor agonists with controls were included in the analysis. The primary outcomes were all-cause mortality and MACE. A frequentist random-effects network meta-analysis was conducted across three nodes. Results: A total of 40 studies, comprising more than 1.9 million patients, were included in the meta-analysis. Compared with control, bariatric surgery was associated with a significant reduction in all evaluated outcomes, including all-cause mortality (HR:0.57, 95%CI:0.51–0.65), MACE (HR:0.54, 95%CI:0.45–0.64), cardiovascular mortality, heart failure hospitalization, myocardial infarction, and stroke. Incretin receptor agonists were also associated with lower all-cause mortality (HR:0.62, 95%CI:0.52–0.74), lower MACE (HR:0.75, 95%CI:0.61-0.92) and reduced heart failure hospitalization. All-cause mortality-representing the most direct and clinically relevant endpoint-did not differ significantly between the two strategies in the exploratory network meta-analysis. Importantly, the network estimates should be cautiously interpreted, given the predominance of observational evidence, substantial heterogeneity, and very low confidence across all comparisons. Conclusion: Bariatric surgery and incretin receptor agonists are associated with substantial reductions in major cardiovascular outcomes in adults with obesity. In head-to-head comparisons, no significant differences were observed in all-cause mortality and stroke. Both strategies provide clinically meaningful benefits.